Robert V. House, MSPH, Ph.D. Robert V. House is President and Chief Scientific Officer of DynPort Vaccine Company LLC, a biotechnology firm that manages product development programs for U.S. government agencies and provides consulting, technical and program management services to companies in the biotechnology and pharmaceutical industries. The DVC portfolio includes innovative solutions for public health threats, featuring vaccines and therapeutics to protect against emerging infectious diseases, biological and chemical warfare threat agents, and seasonal and pandemic influenza. Prior to joining DVC, which is based in Frederick, Md., Dr. House worked at Covance Laboratories in Madison, Wis., and IIT Research Institute in Chicago, Ill., where he managed successful programs in immunotoxicology assessment. He has more than 20 years of experience in biopharmaceutical research and development, specializing in the assessment of inadvertent and therapeutic immunomodulation. Dr. House earned his Master of Science in Public Health and Ph.D. degrees in Medical Parasitology from the University of North Carolina at Chapel Hill School of Public Health. He is the author or co-author of over 100 journal articles, book chapters and books covering immunology, toxicology, infectious disease and biodefense, and has participated in numerous working groups and expert panels in the field of immunotoxicology. |